Structured evidence table for Pterostilbene Menopause Symptoms Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Pterostilbene Menopause Symptoms Randomized Trial | Reduced estradiol levels have been associated with undesirable symptoms of the menopause transition. | 2 | Holmes HE (2026) | Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. |
| Pterostilbene Menopause Symptoms Randomized Trial | As anticipated NRPT intake significantly increased urinary levels of methyl-nicotinamide (Me-NAM) as well as the methylated pyridone carboxamides (Me-PYs) in all groups. | 2 | Holmes HE (2026) | Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. |
| Pterostilbene Menopause Symptoms Randomized Trial | Introduction Nicotinamide adenine dinucleotide (NAD+) is a metabolite of vitamin B3 necessary for the production of key hormones like estradiol. | 2 | Holmes HE (2026) | Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. |
| Pterostilbene Menopause Symptoms Randomized Trial | This structural diversity presents a vast landscape for exploring stilbenes with enhanced potency, improved bioavailability, and targeted therapeutic actions against specific NDs,. | 3 | Begh Md. Zamshed Alam (2024) | Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap |
| Pterostilbene Menopause Symptoms Randomized Trial | They have been found to exert their beneficial effects through various mechanisms, including antioxidant activity, anti-inflammatory effects, enhancement of neurotrophic factors, protein aggregation inhibition, and modulation of autophagy. | 3 | Begh Md. Zamshed Alam (2024) | Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap |
| Pterostilbene Menopause Symptoms Randomized Trial | Despite the promising preclinical evidence, significant research is needed to translate these benefits into clinical applications fully. | 3 | Begh Md. Zamshed Alam (2024) | Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap |
| Pterostilbene Menopause Symptoms Randomized Trial | 1 2 3 4 5 6 7 8 9 Neurological disorders (NDs) encompass a diverse group of debilitating conditions that affect the nervous system, including the brain, spinal cord, nerves, and muscles. | 3 | Begh Md. Zamshed Alam (2024) | Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap |
Source documents